"ONCS..$.30 DD post here. Strong catalysts in the 2nd half of the year with the first being the 8th World Congress of Melanoma (EADO). ONCS is scheduled to present updated Phase II Data in Melanoma on July 18th at 3pm in their Satellite Symposium session. Celgene will also be presenting at the same time.
52wk high is $.485 & 52wk low is $.145. This has a solid catalyst to move it higher with a specific date & timeframe with in the next 60 days. Previous positive results make a good case that the impending results in July could be positive. Over the past month this has traded an avg of 995K shares in volume.
Roth Capital has placed a 12 month price target of $1 with a buy rating. Noble Financial has placed a price target of $2.
Market Data 
Markets 
AI
